Health insurer Cigna said its shareholders Friday morning approved the company’s proposed $67 billion purchase of pharmacy benefits manager Express Scripts.
During a special meeting Friday, about 90% of shareholders approved the merger agreement despite recent pushback from activist shareholder Carl Icahn and Sen. Chuck Grassley from Iowa, the top Republican on the Senate Judiciary Committee.
“Our combined company will enhance Cigna’s differentiated service-based model, fueled by actionable insights and analytics, to drive innovation and meaningful growth in a highly dynamic market environment,” Cigna CEO David Cordani said in a statement. “As a result, we will build more effective partnerships, further improve health outcomes and deliver a superior customer experience.”
The US Department of Justice is performing an antitrust review of the proposed merger, which is expected to be completed later this year. Cigna said it expects the deal, subject to customary closing conditions and regulatory approvals, to close by year-end 2018.
Full Content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI